Drug Profile
Research programme: monoclonal antibodies - MAB Discovery/Sanofi
Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator MAB Discovery; Sanofi
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for research development in Unspecified in France (Parenteral)
- 28 Jan 2020 No recent reports of development identified for research development in Unspecified in Germany (Parenteral)